The post MIND Matters | Quarterly Newsletter | Summer 2025 appeared first on UCI MIND.| UCI MIND
Today in STAT, my colleague and friend, Dr. Jason Karlawish from the University of Pennsylvania Memory Center offers “The way we talk about dementia is about to change completely.” The history of dementia care is less than ideal. Patients struggle to be seen by specialists and many if not most are not even diagnosed. Nihilism is rampant and the resources available to most patients and families on the journey of living with dementia are inadequate. Few treatments have achieved approval for...| UCI MIND
The post Sharing Alzheimer’s Education to the Spanish-Speaking Community in Southern California appeared first on UCI MIND.| UCI MIND
Drs. Kevin Beier and Elizabeth Head, both faculty members of UCI MIND, along with co-investigators Drs. Liz Chrastil and Jing Zhang have been awarded a 4 year NIH grant to study how hyperexcitability in neurons in a unique brain region (the retrospenial cortex thought to be a candidate site where AD pathology begins) contributes to the development of behavioral deficits in 3 mouse models of AD and what the molecular mechanisms are that underlie this effect. To translate their results to AD in...| UCI MIND
UCI MIND is in the spotlight again with the announcement of large collaborative NIA grant to study LATE. Read the article in the UC Irvine News Related posts: MIND Matters | Quarterly Newsletter | Summer 2024 ... Two UCI researchers named as UCI MIND WAM at Cleveland Clinic Women’s initiative recipients Since 2017, UCI MIND has partnered with the Women’s Alzheimer’s Movement (WAM) at Cleveland Clinic, founded by Maria Shriver, to fund the Women’s Initiative. The initiative provides ...| UCI MIND
Breaking the Tyranny of Treatment: A New Perspective on Alzheimer’s Care| UCI MIND
This week NPR published an article describing the reactions of three scientists who learned and subsequently shared their APOE genetic results. What makes this story unique is the way these highly informed people responded to learning their results and their convergent paths of using this knowledge to help advance Alzheimer’s research. The three scientists discovered at various points in their life that they were homozygous for the e4 allele of the apolipoprotein E (APOE) gene. APOE codes...| UCI MIND
Postmortem neuropathological examination of brain tissue is considered the gold standard for understanding many neurological diseases, including Alzheimer’s disease and related dementias (ADRD). Although fluid and imaging biomarkers provide scientists and clinicians with valuable insights into the diseases of the brain, these measures are standardized with brain autopsy to give researchers direct evidence needed to confirm diagnoses, study disease processes, and develop future treatments. N...| UCI MIND
Dr. Vivek Swarup has been awarded an Alzheimer’s Association Research Grant to study oligodendrocyte dysfunction in Alzheimer’s disease (AD). Dr. Swarup writes that Alzheimer’s disease has long been thought of as a problem of nerve cells, but new evidence shows that support cells called oligodendrocytes (OLs) may also play a direct role in driving the disease. These cells help insulate and protect nerves, but in Alzheimer’s, they appear to malfunction and may even produce harmful amyl...| UCI MIND
The post Dr. Karen Lincoln Appointed Co-Chair of New State Council on Toxic Substance Control appeared first on UCI MIND.| UCI MIND
The post UCI MIND researchers identify natural compounds to remove harmful proteins associated with Alzheimer’s disease appeared first on UCI MIND.| UCI MIND
The post UCI MIND Investigators Featured in UCI News for New Study on Sex Differences in AD Pathology Among Individuals with Down Syndrome appeared first on UCI MIND.| UCI MIND
Related posts: Dr. Marcelo Wood quoted in The Transmitter about future PhD admissions in Neuroscience Marcelo Wood, PhD, professor and Chair of the department of Neurobiology and Behavior was quoted in The Transmitter about the decrease in admissions to PhD programs in Neuroscience fields including at UCI. To read the article, click here... Engineered microglia show promise for treating Alzheimer’s and other brain diseases UC Irvine team develop cell-based platform for brain-wide delivery...| UCI MIND
The post Dr. Lisi Flores-Aguilar wins the Postdoctoral Best Poster Award at AAIC appeared first on UCI MIND.| UCI MIND
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.| UCI MIND
University of California, Irvine scientists have unveiled a groundbreaking new way to deliver disease-fighting proteins throughout the brain, potentially revolutionizing the treatment of Alzheimer’s disease and other neurological disorders. By engineering human immune cells called microglia the researchers have created living cellular “couriers” capable of responding to brain pathology and releasing therapeutic agents exactly where needed. The National Institutes of Health-supported stu...| UCI MIND
UC Irvine discovery of ‘item memory’ brain cells offers new Alzheimer’s treatment target Related posts: Dr. Crystal M. Glover will join UCI MIND in 2025 as ORE Core Leader for ADRC We are excited to announce that in January 2025, Dr. Crystal M. Glover will join UCI MIND as the ADRC’s Outreach, Recruitment, and Engagement Core Leader. She will also serve as Associate Professor of Neurology in the UC Irvine School of Medicine. Dr. Glover is a world-renowned applied social psychologis...| UCI MIND
With a $21 million renewal grant from the National Institute on Aging, the University of California, Irvine reinforces its status as a global leader in Alzheimer’s disease and related dementias research. The five-year award will support the continued work of UCI MIND’s Alzheimer’s Disease Research Center, which has been advancing understanding of memory impairments and engaging with the community for more than 40 years. “This funding comes at a crucial moment for our research,” said...| UCI MIND
Newly published research from UCI MIND scientists shows that people carrying a genetic risk factor (APOE4) for Alzheimer’s disease experience faster and more severe memory loss, but other cognitive abilities remain largely unchanged. The study, published in Neurology and led by MD/PhD student Casey Vanderlip and Professor Craig Stark in the Department of Neurobiology and Behavior, found that APOE4 specifically affects how and when memory declines in Alzheimer’s disease. While APOE4 is kno...| UCI MIND
Related posts: MIND Matters | Quarterly Newsletter | Fall 2024 ...| UCI MIND
MIND Matters is a quarterly publication that aims to keep the community abreast of developments in research and happenings across the Institute| UCI MIND
Welcome to UCI MINDcast, UCI MIND’s new video and podcast library with up-to-date content on the latest in Alzheimer’s and dementia research, education and care!| UCI MIND
The Alzheimer’s Disease Parkinson’s Disease (ADPD) 2025 International Conference, held this year in Vienna, Austria, is an annual gathering for scientific experts and industry leaders in neurodegenerative diseases. This conference serves as a platform for sharing the latest scientific breakthroughs, clinical trial results, and innovative treatment strategies. With attendees from over 70 countries giving more than 1,200 poster presentations and 700 oral presentations, ADPD uniquely combine...| UCI MIND
Message from the Director Dear Friends of UCI MIND, Please enjoy the latest issue of MIND Matters from UCI MIND. In this Spring issue, we highlight a number of exciting updates about the impact UCI MIND investigators are having in the field. On the cover, post-doctoral fellow Dr. Claire Butler highlights progress made by the collaborative MODEL-AD group, including a publication she led. Another post-doctoral fellow, Dr. Jessica Noche, highlights an exciting collaboration in which UCI MIND ...| UCI MIND
A June 17 article in the Los Angeles Times highlighted an important safety risk associated with the new class of medications recently approved for treating Alzheimer’s disease. The drugs are anti-amyloid monoclonal antibodies and include aducanumab, donanemab, and lecanemab. Of these, only lecanemab has achieved full FDA approval at the time of writing. The side effects are collectively known as amyloid-related imaging abnormalities, or ARIA, and are potential side effects for each of these...| UCI MIND
Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. One of these trials was conducted at UCI MIND. The efficacy of donanemab in treating early Alzheimer’s disease in people with Mild Cognitive Impairment and mild dementia due to Alzheimer’s disease is largely agreed to...| UCI MIND
For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions is the careful consideration of the available scientific evidence, particularly from randomized clinical trials (RCTs) such as the recent lecanemab trial. Translating RCT results into patient-level decisions, however, can be challenging. This is because trial results tell us about the outcomes o...| UCI MIND
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab had been expected before the end of this month. Though data for donanemab’s ability to lower brain amyloid levels are convincing, the FDA had opted not to grant accelera...| UCI MIND
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new year, UCI MIND and the field of Alzheimer’s disease and related dementias (ADRD) research are abuzz with excitement about progress made and opportunities to further advance our field. At the end of 2023, we held our annual signature fundraising event, the December to Remember Gala. We honored Lauren Miller Rogen and Seth Rogen, the founders of H...| UCI MIND